These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 21221594)

  • 1. Prospective evaluation of free radicals and antioxidant activity following 6-month risedronate treatment in patients with postmenopausal osteoporosis.
    Zinnuroglu M; Dincel AS; Kosova F; Sepici V; Karatas GK
    Rheumatol Int; 2012 Apr; 32(4):875-80. PubMed ID: 21221594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of calcitonin, risedronate, and raloxifene on erythrocyte antioxidant enzyme activity, lipid peroxidation, and nitric oxide in postmenopausal osteoporosis.
    Ozgocmen S; Kaya H; Fadillioglu E; Yilmaz Z
    Arch Med Res; 2007 Feb; 38(2):196-205. PubMed ID: 17227729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study.
    Dundar U; Kavuncu V; Ciftci IH; Evcik D; Solak O; Cakir T
    J Bone Miner Metab; 2009; 27(4):464-70. PubMed ID: 19301089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume.
    Fratzl P; Roschger P; Fratzl-Zelman N; Paschalis EP; Phipps R; Klaushofer K
    Calcif Tissue Int; 2007 Aug; 81(2):73-80. PubMed ID: 17612779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide.
    Polyzos SA; Anastasilakis AD; Bratengeier C; Woloszczuk W; Papatheodorou A; Terpos E
    Osteoporos Int; 2012 Mar; 23(3):1171-6. PubMed ID: 21305266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
    Harris ST; Watts NB; Genant HK; McKeever CD; Hangartner T; Keller M; Chesnut CH; Brown J; Eriksen EF; Hoseyni MS; Axelrod DW; Miller PD
    JAMA; 1999 Oct; 282(14):1344-52. PubMed ID: 10527181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of risedronate treatment on serum osteoprotegerin and bone marker levels in postmenopausal women with osteoporosis.
    Karadag-Saygi E; Akyuz G; Bizargity P; Ay P
    Gynecol Endocrinol; 2011 Dec; 27(12):1033-6. PubMed ID: 21627558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography.
    Borah B; Dufresne TE; Ritman EL; Jorgensen SM; Liu S; Chmielewski PA; Phipps RJ; Zhou X; Sibonga JD; Turner RT
    Bone; 2006 Aug; 39(2):345-52. PubMed ID: 16571382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of antioxidant systems, lipid peroxidation, and nitric oxide in postmenopausal osteoporosis.
    Ozgocmen S; Kaya H; Fadillioglu E; Aydogan R; Yilmaz Z
    Mol Cell Biochem; 2007 Jan; 295(1-2):45-52. PubMed ID: 16841180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of risedronate alone or combined with vitamin K2 on serum undercarboxylated osteocalcin and osteocalcin levels in postmenopausal osteoporosis.
    Kasukawa Y; Miyakoshi N; Ebina T; Aizawa T; Hongo M; Nozaka K; Ishikawa Y; Saito H; Chida S; Shimada Y
    J Bone Miner Metab; 2014 May; 32(3):290-7. PubMed ID: 23846118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
    Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
    Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
    Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
    Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease.
    Palomba S; Orio F; Manguso F; Falbo A; Russo T; Tolino A; Tauchmanovà L; Colao A; Doldo P; Mastrantonio P; Zullo F
    Osteoporos Int; 2005 Sep; 16(9):1141-9. PubMed ID: 15928801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of risedronate on bone marrow adipocytes in postmenopausal women.
    Duque G; Li W; Adams M; Xu S; Phipps R
    Osteoporos Int; 2011 May; 22(5):1547-53. PubMed ID: 20661545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fracture risk remains reduced one year after discontinuation of risedronate.
    Watts NB; Chines A; Olszynski WP; McKeever CD; McClung MR; Zhou X; Grauer A
    Osteoporos Int; 2008 Mar; 19(3):365-72. PubMed ID: 17938986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of weight training on bone mineral density and bone turnover in postmenopausal breast cancer survivors with bone loss: a 24-month randomized controlled trial.
    Waltman NL; Twiss JJ; Ott CD; Gross GJ; Lindsey AM; Moore TE; Berg K; Kupzyk K
    Osteoporos Int; 2010 Aug; 21(8):1361-9. PubMed ID: 19802506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
    Sarioglu M; Tuzun C; Unlu Z; Tikiz C; Taneli F; Uyanik BS
    Rheumatol Int; 2006 Jan; 26(3):195-200. PubMed ID: 15580349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis.
    Harris ST; Watts NB; Li Z; Chines AA; Hanley DA; Brown JP
    Curr Med Res Opin; 2004 May; 20(5):757-64. PubMed ID: 15140343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of risedronate in Japanese male patients with primary osteoporosis.
    Majima T; Shimatsu A; Komatsu Y; Satoh N; Fukao A; Ninomiya K; Matsumura T; Nakao K
    Intern Med; 2008; 47(8):717-23. PubMed ID: 18421187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study.
    Ringe JD; Farahmand P; Faber H; Dorst A
    Rheumatol Int; 2009 Jan; 29(3):311-5. PubMed ID: 18762944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.